iron dextran
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
414
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
September 26, 2026
Baicalein Ameliorates Postmenopausal Osteoporosis With Iron Accumulation by Inhibiting Osteoclastogenesis via Nrf2 Activation.
(PubMed, FASEB J)
- "In vivo, an ovariectomized (OVX) mouse model with iron dextran injection (100 mg/kg/week) was used...Collectively, baicalein ameliorates iron-accumulated postmenopausal osteoporosis by activating the Nrf2 pathway, thereby inhibiting osteoclast differentiation and bone resorption. Baicalein represents a promising multi-target candidate for treating PMOP, especially in patients with concomitant iron accumulation."
Journal • Hematological Disorders • Osteoporosis • Rheumatology
September 25, 2026
Effectiveness and Safety of Intravenous Iron Formulations in Children with Iron Deficiency.
(PubMed, J Pediatr)
- "IVI was effective and well-tolerated in this pediatric cohort. Formulation-specific benefits should be weighed against the risk of increased adverse effects with LMWID and hypophosphatemia with FCM."
Journal • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics • Renal Disease
September 14, 2026
Disruption of cellular iron homeostasis by SRPX2-IRP1 interaction aggravates renal fibrosis in chronic kidney disease.
(PubMed, Cell Death Differ)
- "Notably, therapeutic iron dextran supplementation alleviated UUO-induced renal fibrosis. Collectively, our findings reveal SRPX2 as a key pathogenic factor driving renal fibrosis by disrupting tubular iron homeostasis. Targeting the SRPX2-IRP1 regulatory axis presents a promising therapeutic strategy for slowing CKD progression."
Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • ACO1 • TFRC
September 09, 2026
Parenteral iron overdose: a scoping review.
(PubMed, Clin Toxicol (Phila))
- "Iron sucrose and iron dextran predominated among acute reports, whereas ferric hydroxide polymaltose complex predominated among subacute cases (76.5%)...Given the limited quantity and heterogeneous quality of existing evidence, these observations should be interpreted as hypothesis-generating. Standardized reporting of parenteral iron overdose and multicenter pharmacovigilance collaborations are needed to clarify the true incidence and severity spectrum of this underrecognized medication safety issue."
Journal • Review • Hematological Disorders • Hepatology • Liver Failure
September 05, 2026
Caesalpinia Sappan Wood Extract Alleviates Ferroptosis-Like Oxidative Injury and Restores Macrophage Polarization Balance in Iron Overload-Induced Liver Fibrosis in Rats.
(PubMed, Can J Gastroenterol Hepatol)
- "This study investigated the hepatoprotective effects of C. sappan wood extract (SWE) in an iron dextran-induced rat model of liver fibrosis...SWE performed comparably to deferasirox across most endpoints, with superior MMP-12 recovery. SWE simultaneously attenuates ferroptosis-like oxidative injury and restores macrophage polarization balance, establishing it as a mechanistically coherent multitarget candidate for iron overload-induced liver fibrosis with translational potential beyond that of iron chelation alone."
Journal • Preclinical • Fibrosis • Hematological Disorders • Immunology • Liver Cirrhosis • CD163 • CD86 • GPX4 • IL10 • IL6 • TGFB1
August 11, 2026
Melatonin Suppresses Osteoclastogenesis via Inhibiting Iron/ROS-CREB/PGC-1β-Mediated Mitochondrial Biogenesis.
(PubMed, J Pineal Res)
- "In vivo, ovariectomized (OVX) mice received weekly injections of iron dextran to model moderate iron overload, with or without oral melatonin...In conclusion, melatonin prevents osteoclastogenesis and counters bone loss due to iron accumulation in estrogen‑deficient conditions by chelating iron, scavenging ROS, and blocking the iron/ROS‑activated CREB/PGC‑1β axis, thereby suppressing mitochondrial biogenesis. This study offers a mechanistic explanation for using melatonin as a possible treatment for PMOP, particularly when accompanied by iron overload."
Journal • Hematological Disorders • Osteoporosis • Rheumatology
August 10, 2026
Activating Cannabinoid receptor 2 alleviates iron overload-induced liver damage via dual modulation of STAT3/hepcidin and Nrf2/FPN1 pathways.
(PubMed, Mol Biomed)
- "Male C57BL/6J mice received 100 mg/kg iron-dextran intraperitoneally to establish an iron overload model...Concurrently, CB2R promoted nuclear factor erythroid 2-related factor 2 (Nrf2)/FPN1 signaling in Kupffer cells, decreasing the labile iron pool. These findings identify CB2R as a key regulator of hepatic iron homeostasis and suggest that targeting CB2R may offer a novel therapeutic strategy for iron overload-related diseases."
Journal • Genetic Disorders • Hematological Disorders • Hepatology • Inflammation • Liver Failure • STAT3
July 21, 2026
Naringenin ameliorates iron overload-associated osteoporosis via Tfeb/p62/Nrf2-mediated antioxidation.
(PubMed, Chin J Nat Med)
- "In this study, an in vitro model was established by inducing MC3T3-E1 cells with ferric ammonium citrate (FAC), and an in vivo IOOP model was constructed by inducing mice with iron dextran to investigate the effects and mechanisms of NAR. Functional validation showed that the Nrf2 antagonist ML385 or siRNA could block the effects of NAR without affecting Tfeb expression, whereas the Tfeb inhibitor eltrombopag simultaneously inhibited Nrf2 expression and NAR-induced effects. In conclusion, NAR alleviates iron overload-induced oxidative damage and osteogenic disorders via the Tfeb/p62/Nrf2 pathway, suggesting that it may serve as a potential therapeutic agent for IOOP."
Journal • Hematological Disorders • Osteoporosis • Rheumatology • COL1A1 • KEAP1 • NFE2L2 • NQO1 • RUNX2 • TFEB
July 16, 2026
Management of Iron Deficiency Anemia in Hemodialysis Patients
(clinicaltrials.gov)
- P2 | N=108 | Active, not recruiting | Sponsor: Beni-Suef University
New P2 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
July 08, 2026
The Interaction Between Iron Overload and Lead Exposure on Bone Metabolism.
(PubMed, Front Biosci (Landmark Ed))
- "Iron overload is associated with further alterations in bone metabolic homeostasis under fixed lead exposure, as evidenced by structural deterioration, disruption of trace element homeostasis, and extensive metabolic reprogramming in bone tissue."
Journal • Hematological Disorders • Orthopedics • Osteoporosis • Rheumatology
June 30, 2026
Arterial iron regulates vasodilation during anemia via endothelial holo α-globin.
(PubMed, Blood)
- "Using endothelial specific a-globin knockout mice, we show loss of endothelial a-globin is necessary for increased NO signaling in IDA and for the rescue of NO signaling by iron dextran in female mice. Altogether, the data presented here demonstrate iron is a determinant of endothelial identity and modulates endothelial NO signaling through the regulation of a-globin."
Journal • Anemia • Cardiovascular • Hematological Disorders
June 30, 2026
Protection of Islet Beta Cells from Iron Overload-Induced Injury by Long Non-Coding RNA Maternally Expressed Gene 3.
(PubMed, J Vis Exp)
- "An iron-overload mouse model was induced via intraperitoneal injection of iron dextran...The MEG3 gene may play a protective role against iron-induced islet β-cell apoptosis, potentially involving modulation of the NF-ĸB pathway. This mechanism may contribute to islet dysfunction in patients with β-TM with iron overload."
Journal • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Hepatology • Inflammation • Liver Failure • MEG3
June 26, 2026
Chronic iron overload induces diminished ovarian reserve in mice via iron metabolism dysregulation-mediated oxidative stress and endocrine dysfunction
(PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
- "Iron dextran at 0.5 and 1.0 g/kg can induce chronic, dose-dependent iron overload in mice, which causes systemic iron metabolism disorders and disrupted iron homeostasis to trigger oxidative stress damage and endocrine dysfunction and ultimately induce DOR."
Journal • Preclinical • Endocrine Disorders • Hematological Disorders • Metabolic Disorders • FTH1 • FTL • GPX1 • GPX4 • TFRC
May 12, 2026
UROLITHIN A UNCOUPLES IRON TOXICITY FROM HEPATIC FIBROSIS BY DISRUPTING THE NETOSIS–HMGB1/TLR4 AXIS
(EHA 2026)
- "Methods We employed an iron dextran–induced murine liver fibrosis model coupled with unbiased transcriptomic profiling to identify dominant pathogenic signatures...As depicted, UA exerts a hepatoprotective effect by attenuating ferroptosis and, critically, by potently inhibiting the upstream iron-induced NETosis. By disrupting this neutrophil–macrophage–HSC relay, UA effectively blocks the cascade from chemical iron toxicity to sustained fibrosis."
Fibrosis • Hematological Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • HMGB1 • IL6 • TLR4
June 15, 2026
Documented Adverse Reactions to Different Intravenous Iron Formulations in the Veterans Health Administration: A 10-Year Retrospective Study.
(PubMed, Pharmacoepidemiol Drug Saf)
- "The present study finds varying risk of documented potentially serious ADR and anaphylaxis between available IV iron formulations and aligns with previous data suggesting iron dextran is associated with a higher risk of serious ADR."
Journal • Retrospective data • Immunology
April 13, 2026
Enarodustat Improves Iron Handling and Limits Organ Iron Deposition in CKD Anemia with Iron Overload via Hepato–Spleno–Intestinal Axis Regulation
(ERA 2026)
- "Method A rat model of CKD anemia with graded iron overload was established via 5/6 nephrectomy and iron dextran injection...Changes in the proportion of iron deposition-positive areas in the intestine, liver, spleen, kidney, femur, and heart tissues of chronic kidney disease (CKD) rats after intervention with enarodustat, roxadustat, and recombinant human erythropoietin (rHuEPO) under different degrees of iron overload . Note : A two-tailed test was used. *P<0.05 indicates a statistically significant difference, **P<0.01 indicates a strongly statistically significant difference, ***P<0.001 indicates a very strongly statistically significant difference, and ****P<0.0001 indicates an extremely significant statistically difference."
Anemia • Chronic Kidney Disease • Hematological Disorders • Hepatology • Inflammation • Liver Failure • Nephrology • BMP6 • DMRT1 • EPAS1 • NCOA4
June 10, 2026
Prevalence and trend of anaemia and haemoglobinopathy among pregnant indigenous women in Kuala Kangsar, Perak: A retrospective observational study.
(PubMed, Malays Fam Physician)
- "HbE homozygous status and parenteral iron dextran use were significantly associated with anaemia before delivery. Anaemia and haemoglobinopathy are highly prevalent among pregnant OA women. Identifying their associated factors is crucial for the development of early screening programmes and appropriate management strategies to improve maternal and foetal health outcomes."
Journal • Observational data • Retrospective data • Anemia • Hematological Disorders
May 27, 2026
DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: University of Washington | Trial primary completion date: Oct 2026 ➔ Jan 2027
Trial primary completion date • Anemia • Hematological Disorders
May 12, 2026
Retraction of: Evaluation of the protective effect of the Echinacea Purpurea against apoptosis and inflammation induced by overdose of iron dextran on the hematopoietic system.
(PubMed, J Complement Integr Med)
- No abstract available
Journal • Inflammation
April 25, 2026
Iron overload is associated with increased susceptibility to pulmonary Pythium insidiosum infection in mice.
(PubMed, PLoS Negl Trop Dis)
- "This study established a murine model of pulmonary Pythium insidiosum infection for the first time through intratracheal hyphae inoculation following ID + CTX preconditioning. The findings suggest that iron overload is associated with Th1 immune response suppression and relative Th2 shift, which may be related to increased susceptibility and pathological damage in pulmonary Pythium insidiosum infection. However, further functional experiments are needed to validate causal relationships."
Journal • Preclinical • Hematological Disorders • Infectious Disease • Respiratory Diseases • FER • IFNG • IL10 • IL13 • IL2 • IL4 • IL5 • TNFA
March 27, 2026
Nanoscale artificial antigen presenting cells to expand human antigen-specific cytotoxic CD4 T cells for immunotherapy
(IMMUNOLOGY 2026)
- "Here, we developed a nanoscale platform to expand antigen-specific CD4 T cells with cytotoxicity against cognate target cells. We generated nanoscale artificial antigen-presenting cells (aAPCs) composed of iron-dextran nanoparticles conjugated with peptide-MHC II dimers and anti-CD28 antibodies to provide antigen-specific and co-stimulatory signals... Together, our data show that nanoscale aAPCs reliably expand functional antigen-specific CD4 T cells from human PBMCs, providing both mechanistic insight into cytotoxic CD4 biology and a translational foundation for antigen-specific cell immunotherapy."
Immune Modulation • Immunology • Infectious Disease • Tetanus • CD4 • GZMB • IFNG • IL2 • TNFA
April 15, 2026
Neuroprotective mechanism of acupuncture against brain injury during delayed thrombolysis for acute ischemic stroke.
(PubMed, J Integr Med)
- "Delayed thrombolysis for AIS triggered ferroptosis, accompanied by lipid peroxidation and BBB disruption. The acupuncture exerted neuroprotective effects by regulating ferroptosis, improving iron metabolism and protecting BBB integrity, which is a promising non-pharmacological strategy to enhance the safety of delayed rt-PA thrombolysis for AIS. Please cite this article as: Huang Z, Liu XY, Gao JF, Zhang HT, Huang Y, Wu R, Cheng YY, Zhang ZH, Xu XP, Zhang XC, Ni GX. Neuroprotective mechanism of acupuncture against brain injury during delayed thrombolysis for acute ischemic stroke. J Integr Med. 2026; Epub ahead of print."
Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology • ACSL4 • GPX4 • SLC7A11
April 09, 2026
Mechanisms of resistance to Tmprss6 antisense oligonucleotides in a mouse model of β-thalassemia.
(PubMed, Blood)
- "To determine whether iron overload alone blunted the effects of Tmprss6 ASO, we assessed the responses of C57BL/6 mice after 10 mg of iron dextran or 5000 ppm high iron diet. Unlike iron-adequate mice, iron-overloaded mice already had high phospho-Smad and hepcidin, with no further increase after Tmprss6 ASO treatment, and no effect on erythroid or iron parameters.Higher ERFE concentrations and more severe iron overload may be responsible for diminished benefits of Tmprss6 ASO in human NTDT."
Journal • Preclinical • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • ERFE • TMPRSS6
April 06, 2026
Severe Iron Deficiency Anemia in a Jehovah's Witness diagnosed with Peutz-Jeghers Syndrome.
(PubMed, J Brown Hosp Med)
- "A comprehensive transfusion-free anemia management protocol, including intravenous iron dextran, erythropoiesis-stimulating agents, vitamin supplementation, and minimization of iatrogenic blood loss, resulted in hemoglobin to improve to 10.9 g/dL at 4 weeks and 14.0 g/dL at 4 months, enabling elective robotic-assisted jejunal polypectomy. This case highlights Peutz-Jeghers syndrome as an uncommon cause of severe iron deficiency anemia and illustrates a multidisciplinary, ethically sensitive, transfusion-sparing approach to managing life-threatening anemia in a Jehovah's Witness patient."
Journal • Anemia • Gastrointestinal Disorder • Hematological Disorders • Pain • STK11
January 10, 2026
A HEAVY PRICE FOR HEAVY METAL: INTRAVENOUS IRON INDUCED TYPE II KOUNIS SYNDROME
(ACC 2026)
- "Case: A 62-year-old woman with drug-induced lupus admitted for clonidine-associated angioedema was receiving IV iron dextran for anemia when she developed acute respiratory distress, chest pain, tachycardia, and hypoxemia, requiring epinephrine, steroids, antihistamines and BiPAP. Type II KS results from allergen-triggered, mast-cell-mediated plaque/thrombus disruption causing ischemia with variable, often underdiagnosed presentations. Temporal association with an allergic trigger is key, and further studies should clarify epidemiology and standardize treatment."
Acute Coronary Syndrome • Acute Respiratory Distress Syndrome • Cardiovascular • Heart Failure • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Myocardial Infarction • Respiratory Diseases • Thrombosis • Vasculitis • MPO
1 to 25
Of
414
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17